Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00393380 · ClinicalTrials.gov registry record · Phase 2
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
A Phase 2 study, sponsored by The Emmes Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00393380: Clinical Trial Phase 2 study, sponsored by The Emmes Company.
NCT00393380 is a Phase 2 study that was terminated before completion, run by The Emmes Company. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00393380, a Phase 2 study, was terminated before completion, sponsored by The Emmes Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the addition of parathyroid hormone after a sequential cord blood transplant will improve engraftment, which is the ability of the transplanted stem cells to grow and to successfully begin producing new blood cells.
Primary Outcome
Median time to neutrophil engraftment (defined as an absolute neutrophil count \[ANC\] greater than 500)
Interventions
- DRUG Parathyroid Hormone (teriparatide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-09 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Why NCT00393380 stopped before completion
NCT00393380 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Parathyroid Hormone (teriparatide) is the first listed.
NCT00393380 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00393380 about?
NCT00393380 is a clinical study titled "Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor". The purpose of this study is to determine whether the addition of parathyroid hormone after a sequential cord blood transplant will improve engraftment, which is the ability of the transplanted stem cells to grow and to successfully begin producing new blood cells.
What is the current status of trial NCT00393380?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2006-09. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00393380?
The interventions under investigation include: Parathyroid Hormone (teriparatide) (DRUG).
Who is sponsoring clinical trial NCT00393380?
This trial is sponsored by The Emmes Company, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00393380's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia